The MRCF is a unique collaboration between CSL, major Australian superannuation funds, the Australian and New Zealand governments, Australian state governments and over 40 leading medical research institutes and research hospitals.
The MRCF supports the development and commercialisation of early-stage biomedical discoveries originating from member research organisations, providing both capital and expertise to guide the successful development of new therapies.
40+ Medical research institutes and hospitals
ACT Government
Queensland Government
Victorian Government
NSW Government Health
Ministry of Business, Innovation & Employment NZ
Brandon Capital
Australian Government
Australian Super
Hesta
Host Plus
Statewide Super
CSL
The Future Industries Institute (FII) focuses on addressing real world issues and partnering with industry and end-users. FII provides industry with a “go to” destination to work on improvements, innovations and breakthroughs.
ViewMelbourne Health’s research vision is to be a leading centre for to delivery of translational health, research and education.
ViewIMB is a global leader in multidisciplinary life sciences research, bringing together 500 researchers from across the globe for disease discovery, application and sustainable futures. Formed in 2000 as an initiative of The University of Queensland, State and Federal Governments and private philanthropy, IMB is one of the largest life sciences institutes in the Asia-Pacific region. It has capitalised on one of the greatest periods of discovery in history – the genetic and molecular basis of life and its diversity.
View
Brandon Captial Partners Pty Ltd manages the MRCF Collaboration, providing seed and venture capital investment to support the development and international growth of Australian and New Zealand life science companies.
Learn more about the Brandon Capital Team
Through the internship it was fantastic to understand what Brandon are looking for in the projects they fund. The learnings from the internship program will be applied to the new projects we develop, both in reviewing the opportunity and developing a solid business plan that will increase the commercial success.
The internship was a valuable experience that filled a critical gap in my knowledge of how early-stage life science technologies are commercialised. Up to this point, my experience was from a technology development perspective, and I did not have a full understanding of what investors were seeking in potential investments. The internship experience is immeasurable and will pay dividends well into the future.
The internship was an excellent learning and development opportunity. I greatly improved my understanding of the venture capital financing model and elements such as valuation, due diligence, market analysis and drug development. The MRCF internship program also enabled me to expand my national commercialisation networks and work alongside experienced biotech investors.
